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Abstract
An important neuropathological feature of neuroinflammatory processes that occur during e.g. Multiple Sclerosis (MS) is the
formation of an astroglial scar. Astroglial scar formation is facilitated by the interaction between astrocytes and extracellular
matrix proteins (ECM) such as fibronectin. Since there is evidence indicating that glial scars strongly inhibit both axon
growth and (re)myelination in brain lesions, it is important to understand the factors that contribute to the interaction
between astrocytes and ECM proteins. Tissue Transglutaminase (TG2) is a multifunctional enzyme with an ubiquitous tissue
distribution, being clearly present within the brain. It has been shown that inflammatory cytokines can enhance TG2 activity.
In addition, TG2 can mediate cell adhesion and migration and it binds fibronectin with high affinity. We therefore
hypothesized that TG2 is involved in astrocyte-fibronectin interactions. Our studies using primary rat astrocytes show that
intracellular and cell surface expression and activity of TG2 is increased after treatment with pro-inflammatory cytokines.
Astrocyte-derived TG2 interacts with fibronectin and is involved in astrocyte adhesion onto and migration across
fibronectin. TG2 is involved in stimulating focal adhesion formation which is necessary for the interaction of astrocytes with
ECM proteins. We conclude that astrocyte-derived TG2 contributes to the interaction between astrocytes and fibronectin. It
might thereby regulate ECM remodeling and possibly glial scarring.
Citation: van Strien ME, Breve´ JJP, Fratantoni S, Schreurs MWJ, Bol JGJM, et al. (2011) Astrocyte-Derived Tissue Transglutaminase Interacts with Fibronectin: A
Role in Astrocyte Adhesion and Migration? PLoS ONE 6(9): e25037. doi:10.1371/journal.pone.0025037
Editor: Colin Combs, University of North Dakota, United States of America
Received March 25, 2011; Accepted August 26, 2011; Published September 16, 2011
Copyright:  2011 van Strien et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This study was financially supported by the Dutch MS Research Foundation (grant 08-635) (www.MSresearch.nl). The funders had no role in study
design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: amw.vandam@vumc.nl
¤a Current address: Department of Astrocyte Biology and Neurodegeneration, Netherlands Institute for Neuroscience, Amsterdam, The Netherlands
¤b Current address: Galapagos B.V., Leiden, The Netherlands
Introduction
Astrocytes within the brain are considered to be important for
maintaining an environment in which neurons, other glial cell
types and the brain endothelium function and interact properly
[1]. Injury to the central nervous system (CNS) often results in a
characteristic astroglial response, i.e. the astrocytes become
activated, migrate, and form a dense network of hypertrophic
cells, the astroglial scar [2–4]. Additional cell types including
macrophages, microglia, oligodendrocytes, and meningeal fibro-
blasts contribute to the glial scar [5], but astrocytes predominate
and are the focus of the present study. The astroglial scar consists
of a fine meshwork of astrocyte processes strongly interwoven and
bound together by tight and gap junctions, surrounded by
extracellular matrix (ECM) [5–7].
In situations of chronic neuroinflammation, e.g. Multiple
Sclerosis (MS), when inflammatory cytokines are produced and
released within the CNS [8], sustained and excessive deposition of
ECM proteins such as fibronection and activation of astroglial cells
can create an environment in which an astroglial scar is formed.
Moreover, the cytokine interleukin-1b (IL-1b) has been shown to
promote the reactive astrocytic phenotype and adhesion of
astrocytes onto fibronectin (Fn) or laminin [9]. The astroglial scar
acts as a physical or biochemical barrier that impedes tissue repair
[5]. For instance, a reduction in migration and differentiation of
oligodendrocyte precursor cells (OPCs) has been described [10–
12], as well as attenuated myelination of axons by oligodendro-
cytes [5].
Thusfar, studies on astrogliosis and down-stream mechanisms
involved in the interaction between astrocytes and ECM molecules
focus on relatively acute (hours) effects. However, patients
suffering from neuroinflammation and/or brain injury experience
long-term consequences of their disease i.e. impaired regeneration.
In that respect, we are interested in the role of tissue
Transglutaminase (tTG or TG2) in the interaction of astrocytes
with ECM molecules, e.g. Fn after (relatively) long-term cytokine
treatment. It has been shown that upon treatment of different cell
types with cytokines, TG2 expression and activity was elevated for
a longer period of time, i.e. up to 7 days [13,14] which may be
more reflecting the pathological situation in humans.
TG2 is an ubiquitous member of a family of Transglutaminase
enzymes. Its functional role remains to be fully established, but
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TG2 is well known for its ability to posttranslationally modify
proteins in a calcium-dependent manner. TG2 can cross-link
proteins, amidate or deamidate proteins, it can bind and hydrolyse
GTP to mediate cell signalling, and it has isopeptidase activity
[15]. TG2 is mainly expressed intracellularly, but it can also be
found extracellularly in the extracellular matrix [15]. In addition,
it has been shown that TG2 is present on the surface of monocytes
[16], monocyte-derived dendritic cells and macrophages [17],
endothelial cells [18] and fibroblasts [19]. Since TG2 is present on
the cell surface of these cell-types and has a Fn binding site located
in the N-terminal domain, a prominent role for TG2 in mediating
cell adhesion has been put forward [16,19]. Besides the interaction
of TG2 with Fn to facilitate cell adhesion, it is involved in
numerous other adhesion-dependent phenomena including cell
migration, extracellular matrix assembly [20], and cell signalling
[21]. Cytoskeletal reorganization and focal adhesion dissolution
[22,23] are required to mediate those processes.
Based on these considerations, in our quest to unravel the
mechanism(s) that contribute to relatively long-term astroglia
activation and astrocyte-ECM interactions that could ultimately
contribute to astroglial scar formation, we hypothesize that the
enzyme TG2 is an important player. To investigate this issue, we
used primary cultured rat astrocytes, and observed cytokine-
induced enhanced intracellular and surface expression of active
TG2. Furthermore, TG2-mediated cross-linking activity resulted
in enhanced astrocyte adhesion onto and migration across Fn,
most likely mediated via effects on focal adhesion-related vinculin.
Materials and Methods
Primary rat astrocyte culture and cytokine treatment
Primary cultures of astrocytes were prepared from newborn (2-
day old) Dark Agouti rats (Harlan CPB, Zeist, The Netherlands) as
described [24]. In short, cerebral cortices were cleared from
adhering meninges and blood vessels and dissociated using 0.25%
trypsin (Sigma-Aldrich, St. Louis, MO) in phosphate-buffered saline
(PBS). Cells were plated in poly-L-lysine (15 mg/ml (0,4 mg/cm2/
ml); Sigma-Aldrich) coated T75 culture flasks (Nunc, Hamstrop,
Denmark) and incubated at 37uC in humidified air containing 5%
CO2. The culture medium consisted of Dulbecco’s modified Eagle’s
medium (DMEM)-F10 (Gibco, Life Technologies, Breda, The
Netherlands), supplemented with 10% v/v heat-inactivated fetal
calf serum (FCS) (Gibco), 2 mM L-glutamine (Sigma-Aldrich), 50
Units/ml penicillin (Sigma-Aldrich) and 50 mg/ml streptomycin
(Gibco). The medium was changed 1 day after seeding. After 8 days
of culture, pure astrocytes were obtained by shaking the flasks at
37uC on a rotary platform (Heidolph Unimax 2010) at 240 rpm for
16 h to remove microglia and oligodendrocyte progenitors.
Astrocytes can be further purified by treatment (overnight (o/n),
37uC) treatment with 5 mM leucine methyl ester (LME, Sigma-
Aldrich) in serum free medium. Fresh medium was added to the
flasks and cells were ready for use in further experiments. Primary
astrocytes were used for a maximum of 5 passages.
For experiments with primary rat astrocytes, cells were plated
onto wells that were coated with 2 mg/mm2 Fn (Sigma-Aldrich) for
1 h at 37uC. Astrocytes were cultured in medium alone (control) or
the presence of rat recombinant (rr) TNFa (50 ng/ml; Pharmin-
gen, BD Biosciences, Breda, The Netherlands), rr IFNc (50 ng/
ml; R&D systems, Abingdom, United Kingdom), rr IL-1b, (50 ng/
ml; gift from Glaxo IMB, Geneva, Switzerland) or combinations of
the various cytokines (50 ng/ml each) for 48 h.
To determine the role of TG2 in adhesion to and migration
over Fn, astrocytes were co-incubated with 0.5 mM KCC009, a
specific irreversible inhibitor of TG2 activity [25] (gift from Alvine
Pharmaceuticals, San Carlos, CA, USA), diluted in 0.2% DMSO
or with 0.2% DMSO only (vehicle).
Ethics statement
All experiments carried out in this study were strictly performed
in a manner to minimize suffering of laboratory rats. The protocol
was approved by the Animal Experiment Committee of the VU
University Medical Center, Amsterdam, The Netherlands (ap-
proval ID: ANW 06-10).
TG2 immunocytochemistry
Untreated primary astrocytes were cultured in Fn coated 8-well
chamber slides (Nunc) at 37uC. After 24 h, cells were fixed with
4% paraformaldehyde in 0.1 M phosphate buffer (pH 7.6) for
15 min and subsequently rinsed with PBS. The cells were
incubated with mouse anti-TG2 (Ab3, 10 mg/ml; Labvision) in
PBS/2% bovine serum albumin (Sigma-Aldrich) for 4 h at 4uC.
After washes in PBS, the cells were incubated with biotinylated
donkey anti-mouse IgG’s (1:500; Jackson laboratories) for 1 h at
room temperature (RT) followed by an hour incubation with
Alexa Fluor 488-coupled streptavidin (1:400; Invitrogen) at RT.
Cells were washed with PBS and slides were embedded in
vectashield (Vector Laboratories Inc., Burlingame, CA, USA).
Pictures were taken using a Colorview II digital camera (Olympus,
Soft Imaging System, Munster, Germany) and Cell*F software
(Olympus Soft Imaging Solutions GmbH).
Semi-quantitative RT- PCR
For semi-quantitative RT-PCR, 16106 astrocytes were homog-
enized in Trizol reagent (Invitrogen, Carlsbad, USA) and total
RNA was isolated as described by the manufacturer. RNA
concentration and purity was determined by measuring the
absorbance at 260 nm and 280 nm in a microtiter plate reader
(Spectramax 250, Molecular Devices). One mg of RNA was reverse
transcribed into cDNA using the Reverse Transcription System
(Promega, Madison, WI, USA) with oligo-dT primers and AMV
enzyme, according to the manufacturer’s instructions. The PCR
reaction was carried out at 42uC for 30 min, followed by
deactivation of the enzyme at 95uC for 5 min and 4uC for
5 min. For the PCR reaction, the SYBR Green PCR Core
reagents kit (Applied Biosystems, Foster City, CA, USA) was used.
Intron-spanning primers were designed using Primer Express
Software (Applied Biosystems) and purchased from Eurogentec
(Seraing, Belgium). Amplification of cDNA was performed in
MicroAmp Optical 96-well Reaction Plates (Applied Biosystems)
on an ABI PRISM 7700 Sequence Detection System (Applied
Biosystems). The reaction mixture (20 ml) was composed of 16
SYBR Green buffer, 3 mM MgCl2, 875 mM dNTP mix, 0.3 U
AmpliTaq gold, 0.12 U Amperase UNG, 15 pmol of each primer
(Table 1), 12.5 ng cDNA and nuclease free H2O. The reaction
conditions were an initial 2 min at 50uC, followed by 10 min at
95uC and 40 cycles of 15 sec at 95uC and 1 min at 59uC. The
mRNA expression levels were quantified relatively to the level of
the housekeeping gene glyceraldehyde-3-phosphate-dehydroge-
nase (GAPDH) using the following calculation:
2{ Treshold cycle of t arg etmRNA{Treshold cycle of GAPDHð Þ| 100%
Western blotting
Astrocytes were homogenized in ice-cold lysis buffer containing
10 mM Tris/HCl pH 7.5, 150 mM NaCl, 1 mM EDTA, 1 mM
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DTT, 100 mM PMSF, 10 mg/ml leupeptin, 10 mg/ml pepstatin
and 10 mg/ml aprotinin (all from Sigma-Aldrich). Homogenates
were cleared by centrifugation at 14,000 rpm for 30 min at 4uC,
and protein concentrations of supernatants were determined by
the BCA method (Pierce Biotechnology, Etten-Leur, The Nether-
lands). Of each sample, 10 mg of protein was subjected to 10%
SDS-polyacrylamide gel electrophoresis (SDS-PAGE) and trans-
ferred to a polyvinylidene difluoride (PVDF) membrane (Invitro-
gen, Carlsbad, CA, USA). Membranes were incubated with
primary mouse anti-TG2 (Ab3, 1:1,000; Labvision, Fremont, CA,
USA), mouse anti-vinculin (1:400; Abcam, Cambridge, UK), or
mouse anti-b-actin (1:2,000; Abcam). For subsequent antigen
detection, blots were incubated for 2 h with corresponding goat
anti-mouse Immunoglobulins/HRP (1:1000; Dako, Glostrup,
Denmark). Bands were visualized using the enhanced chemilumi-
nescence (ECL) detection system SuperSignal West Dura (Pierce
Biotechnology) and a Chemidoc image capture system (Bio-Rad,
Veenendaal, The Netherlands). Signal intensity of the bands was
semi-quantified using Quantity One software (Bio-Rad).
TG2 ELISA
TG2 protein levels were measured in cell lysates using a
sandwich enzyme-linked immunosorbent assay (ELISA) specific
for TG2 as described previously [26]. Briefly, astrocytes were
homogenized in ice-cold lysis buffer as described for western blot.
Homogenates were cleared by centrifugation (14,000 rpm for
30 min at 4uC) and protein concentrations of supernatants were
determined by the BCA method (Pierce Biotechnology). Of each
sample, 10 mg of protein was loaded into the assay. An
immunoaffinity-purified polyclonal goat anti-TG2 antibody
(1:1,000; Upstate, Millipore, USA) was used as coating antibody
and a monoclonal mouse anti-TG2 antibody (Ab2, 1:1,000;
Labvision) was used as detecting antibody. Recombinant human
TG2 (Zedira Biotec GmbH, Darmstadt, Germany) was used as a
standard.
TG activity assay
To measure TG activity, astrocytes were treated with cytokines
at 37uC for 48 h. Subsequently, cells were homogenized in ice-
cold lysis buffer as described for western blot. Homogenates were
centrifuged for 30 min at 14,000 rpm at 4uC, and protein
concentrations of supernatants were determined by the BCA
method (Pierce Biotechnology). Activity was measured by using
the TG Covtest TCMA (Transglutaminase Colorimetric Micro-
assay; Covalab, Villeurbanne, France) following manufacturer’s
protocol [27]. In short, immobilized CBZ-Gln-Gly was coated
onto the wells as the first TG substrate. Subsequently, 10 mg of
protein from each sample was added/well, followed by addition of
biotinylated cadaverine as a second TG substrate. After 30 min
incubation at 37uC, plates were washed with Tween-20 buffered
saline (TTBS) and 100 ml streptavidin-labelled peroxidase (HRP)
diluted in TTBS was added to the wells for 15 min. After washing,
peroxidase activity was revealed using 100 ml of 0.01% H2O2 as
HRP substrate and (0.1 mg/ml) tetramethyl benzidine as electron
acceptor (chromogen). The reaction was stopped by the addition
of 50 ml of 2.5 N H2SO4. TG activity was detected by absorbance
measurement of streptavidin-labelled peroxidase activity in each
well on a microplate reader (SpectraMax 250, Molecular Devices)
at 450 nm. Guinea pig TG2 (T5398, Sigma-Aldrich) was used as a
standard. One unit of guinea pig TG2 will catalyze the formation
of 1.0 mmole of hydroxamate per min from Na-Z-Gln-Gly and
hydroxylamine at pH 6.0 at 37uC.
Detection of immunofluorescent TG2 on the cell surface
For immunofluorescent surface labeling of TG2, untreated
astrocytes were washed with TBS and incubated on ice with a
mouse monoclonal anti-TG2 antibody (Ab1, 1:1,000; Labvision)
for 2 h. Cells were washed with TBS, followed by incubation for
1 h on ice with goat anti mouse coupled to Alexa Fluor-488
(1:400; Invitrogen). Subsequently, cells were washed with TBS and
fixed for 10 min with 4% paraformaldehyde (PFA). After washing
with H2O, sections were embedded in Vectashield mounting
medium (Vector Laboratories) and examined on a Leica confocal
laser scanning microscope (Leica, Rijswijk, The Netherlands).
Cell surface biotinylation and immunoprecipitation
To determine TG2 expression on the cell surface, cells were
plated in Fn coated wells of a 6-well plate (2.56105 cells/well,
Nunc), and allowed to adhere o/n. Cells were incubated with
cytokines (50 ng/ml) for 48 h. Subsequently, cells were washed
with ice-cold PBS. Cell surface proteins were biotinylated by
incubating the astrocytes for 20 min with 0.2 mg/ml Sulfo-NHS-
LC-biotine (Pierce Biotechnology) in PBS at 4uC. The reaction
was stopped by addition of 100 mM mM Tris-HCl, pH 7.5.
Surface-biotinylated cells were washed with in PBS at 4uC and
lysed in ice-cold lysis buffer as described for western blot. Cell
lysates were cleared by centrifugation (14,000 rpm for 30 min at
4uC). Then, 100 mg of total cell protein was taken for each
immunoprecipitation. Cell lysates were incubated with 100 ml
50% Neutravidin agarose beads (Pierce Biotechnology, pre-
washed with TBS/1% SDS) for 3 h at RT. Beads were washed
with TBS/1% SDS and then with TBS. Beads were collected in
46LDS sample buffer (Invitrogen) containing 50 mM DTT and
boiled for 10 min. Samples were centrifuged for 5 min at
12,000 rpm at 4uC and levels of surface TG2 were detected using
gel-electroforesis and western blot as described above.
Flow cytometry
To study TG activity on the surface of astrocytes after treatment
with various cytokines and the effect of inhibition of TG2 activity,
the incorporation of a biotinylated primary amine substrate 5-
(biotinamido) pentylamine (BAP) of TG was measured using flow
cytometry (FACS). Detection of BAP by FACS analysis reflects
TG activity on the cell surface of astrocytes. Therefore, astrocytes
were plated onto Fn coated wells and cultured in the presence of
TNFa, IL-1b or the combination of both for 48 h. After
incubation, cells were washed with PBS containing 0.1% glucose
and detached with 10 mM EDTA in PBS/0.1% glucose.
Subsequently, cells were counted and 1.56105 cells were
resuspended in 1 ml AC-buffer containing PBS/0.1% glucose
containing 1.2 mM CaCl2 and 0.5 mM MgCl2. Then, cells were
Table 1. Oligonucleotide primers used for amplification of
cDNAs1.
rat cDNA Sequence forward 59 to 39 Sequence reverse 59 to 39
GAPDH TCAAGGGCATCCTGGGCTAC CGTCAAGGTGGAGGAGTGG
TG1 ACCAGCAGTGGCATCTTC AATGAAAGGTGTGTCATACTTC
TG2 AGAGGAGCGGCAGGAGTATG AGGATCCCATCTTCAAACTGC
TG3 GAAGTCAAGGTGTGTTCC AGATGAAGATCATGTCGAA
TG6 TCAATCCCTGGTGCCCAGAG ACGCCTCGGAAGATGATGCC
FXIIIa TCACTGCACGCATCAACGAGAC TGCCTCGGACCTTGATGGTGAC
1Primers were designed using the Primer Express program (Applied Biosystems)
and purchased from Eurogentec (Seraing, Belgium).
doi:10.1371/journal.pone.0025037.t001
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pre-incubated with 0.5 mM KCC009 or vehicle in AC-buffer at
37uC for 15 min. Finally, BAP (Pierce Biotechnology) was added
to the cells in a final concentration of 0.2 mM and cells were co-
incubated for 1 h at 37uC with vehicle or KCC009. After
incubation, cells were placed on ice, washed with AC-buffer
containing 0.1% BSA and subsequently stained with streptavidin-
Alexa Fluor-488 (1:300; Invitrogen) at 4uC for 30 min. Cells were
washed with AC-buffer containing 0.1% BSA and resuspended in
AC-buffer/0.1% BSA containing 1 mg/ml propidium iodide (PI,
Sigma) to stain apoptotic cells. Then, flow cytometry was
performed on a FACScan (BD Biosciences) and data were
analyzed using The Windows Multiple Document Interface
(WinMDI) software (freeware designed by J. Trotter to analyze
flow cytometric listmode data files).
Analysis gates were set on propidium iodide (PI) negative cells.
Three independent experiments were performed and in each
experiment, BAP+vehicle-treated control cells were set at 100%.
BAP incorporation assay
To study whether active TG2 is involved in the interaction
between astrocytes and Fn, the incorporation of the biotinylated
amine substrate BAP into Fn was measured [28]. In short, 48 h-
cytokine treated rat astrocytes were detached with 10 mM EDTA,
resuspended in fresh medium and plated onto Fn coated 96-well
plates (50 ml/well corresponding to ,3.5*104 cells/well) in the
presence of 0.5 mM KCC009 in 0.2% DMSO or 0.2% DMSO
only (vehicle). BAP was added directly (0.1 mM; Pierce Biotech-
nology) and cells were incubated for 1 h at 37uC. Subsequently,
cells were washed with PBS containing 3 mM EDTA and then
incubated for 20 min with 0.1% sodiumdeoxycholate (Sigma) in
PBS containing 3 mM EDTA. Supernatant and cells were
removed and the plate was washed with 0.1 M Tris-HCl
(pH 7.4). Then, the plate was incubated for 1 h at 37uC with
streptavidin poly-HRP (1:10,000 in Tris/HCl). After washing with
Tris/HCl, peroxidase activity was revealed using 0.01% H2O2
and 0.1 mg/ml tetramethyl benzidine (chromogen). The reaction
was stopped by the addition of 50 ml of 2.5 N H2SO4 and OD was
measured on a microplate reader (SpectraMax 250, Molecular
Devices) at 450 nm. Three independent experiments with
duplicate measurements were performed for each treatment.
Astrocyte adhesion onto Fn
Astrocyte adhesion was studied as described [29]. In short, 96-
well plates were coated with Fn (Sigma-Aldrich) for 1 h at 37uC.
Primary rat astrocytes that had been treated with cytokines for
48 h were detached with 2 mM EDTA and plated onto Fn-coated
wells (56104 cells/well) in serum free medium. Cells were allowed
to adhere for 3 h at 37uC in the presence of 0.5 mM KCC009 or
vehicle. After 3 h, cells were washed with PBS and fixed with 4%
PFA in 0.1 M phosphate buffer for 30 min at RT. Cells were
stained with 100 ml crystal violet solution (0.5 gr/100 ml 70%
EtOH) for 40 min. Cells were washed with PBS and crystal violet
was extracted from the cells with 100 ml 30% acetic acid. The
absorbance was measured on a microplate reader (SpectraMax
250, Molecular Devices) at 540 nm. Three independent experi-
ments with duplicate measurements were performed for each
treatment.
Astrocyte viability measurements
The effect of KCC009 treatment on cell viability was
determined by PI exclusion assay. Rat astrocytes were plated in
a 96-well plate (20,000 cells/well) and allowed to adhere for 24 h
in serum free medium. Medium was replaced with PBS containing
0.5 mM MgCl2, 1.2 mM CaCl2, 0.1% glucose, 40 mg/ml PI
(Sigma) and 0.5 mM KCC009 or vehicle. During an incubation
period of 24 h at 37uC, PI fluorescence was measured at 30 min
intervals, using a Fluostar OPTIMA microplate reader with an
excitation wavelength of 544 nm and an emission of 612 nm.
Average slope/minute was measured per 30 minute interval and
average slope/minute in 24 h was determined (F-average). A total
of 160 mM digitonin was then added for 20 min to permeablize all
cells and fluorescence measurements were performed to obtain a
maximal fluorescent signal (Fmax). Percentage viability was
calculated as: 1002(F-average/Fmax-blank)6100% [30].
Astrocyte migration across Fn
Astrocyte migration was studied as described [29]. In short,
permanox Chamberslides (4-wells, Nunc) were coated with 2 mg/
cm2 Fn (Sigma-Aldrich) for 1 h at 37uC. Primary rat astrocytes
were plated onto the Fn-coated wells (26105 cells/well) and
allowed to adhere for 24 h. Then, cytokines were added to the
cells. After 24 h, 0.5 mM KCC009 or vehicle was added to the
cells in serum-free medium and a scratch wound was made in each
well by using a sterile 10 ml pipet-tip (Corning). At 0 and 16 h after
wound induction, cells were fixed with 4% PFA for 20 min. Cells
were washed with PBS and subsequently stained with rhodamine-
phalloidin (1:300; Invitrogen) for 1 h at RT, washed with PBS and
embedded in vectashield (Vector Laboratories). Pictures were
taken using a Colorview II digital camera (Soft Imaging System,
Gmbh, Germany). The diameter of the wound (where no cells
were present) was measured using Cell*F software (Olympus Soft
Imaging Solutions GmbH, Germany). Five random 206 fields per
culture condition were captured, and mean wound diameter was
assessed in each field and averaged over the five fields.
Bromodeoxyuridine labeling assay
To determine the effect of KCC009 treatment on astrocyte
proliferation, primary rat astrocytes were plated onto the Fn-
coated wells (26105 cells/well) and allowed to adhere for 24 h.
Then, cytokines were added to the cells. After 24 h, 0.5 mM
KCC009 or vehicle was added to the cells in serum-free medium
and a scratch wound was made in each well by using a sterile 10 ml
pipet-tip (Corning). At 1 h after wound induction, 10 mM
bromodeoxyuridine (BrdU; Sigma) was added for 15 h to label
mitotic cells. Cultures were subsequently washed with PBS and
fixed with 4% PFA for 20 min, permeabilized with 0.5% Triton
X-100 (Sigma-Aldrich) in PBS for 10 min, followed by 20 min
incubation with 1 N HCl, and a 10 min neutralisation step with
0.1 M borate buffer and blocked with 3% BSA in PBS/0.5%
Triton X-100 for 1 h. To identify BrdU, astrocytes were incubated
with rat anti-BrdU (1:100; Abcam) in PBS/0.5% Triton X-100
with 1% BSA 1 h at RT, washed with PBS/0.5% Triton X-100
followed by incubation with goat anti-rat FITC (1:100: Jackson).
Cells were washed twice with PBS/0.5% Triton X-100 once with
PBS and embedded in Dapi-containing Vectashield (Vector
Laboratories). Immunofluorescent staining was visualized using a
Leica confocal microscope (Leica Microsystems). In five random
206 fields per culture condition, the number of proliferative cells
(%) was calculated as follows: (number of BrdU positive cells/
number of dapi positive nuclei)6100%.
Visualization of F-actin and vinculin
The effect of inhibition of TG2 activity by KCC009 on focal
adhesion formation was visualized by vinculin immunocytochem-
istry. Cells were plated on Fn-coated (2 mg/cm2, Sigma-Aldrich) 8-
well chamber slides (Labtek, Nalge Nunc International, 26104
cells/well). After 24 h, medium was replaced by serum free
medium and the cells were incubated at 37uC with cytokines for
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48 h. Then, the cells were incubated with 0.5 mM KCC009 in
0.2% DMSO or 0.2% DMSO only (vehicle) in serum free medium
for 1 h and subsequently fixed for 20 min with 4% PFA,
permeabilized with 0.5% Triton X-100 (Sigma-Aldrich) in PBS
for 10 min and blocked with 3% BSA in PBS/0.5% Triton X-100
for 1 h. To identify focal adhesions, astrocytes were incubated with
mouse anti-vinculin antiserum (1:400; Abcam) in PBS/0.5%
Triton X-100 containing 1% BSA o/n at 4uC, washed with PBS/
0.5% Triton X-100 followed by incubation with donkey anti-
mouse Alexafluor-488 (1:1,000; Invitrogen). Slides were washed
and to identify F-actin cytoskeleton filaments, astrocytes were
subsequently stained with rhodamine-phalloidin (1:300; Invitro-
gen) for 1 h at RT, washed with PBS and embedded in
Vectashield (Vector Laboratories). Immunofluorescent staining
was visualized using a Leica confocal microscope (Leica Micro-
systems). Three independent experiments were performed.
Statistics
Where appropriate, data were analyzed by one-way or two-way
ANOVA, followed by a t-test for independent measurements (Fisher’s
LSD test). The statistical evaluation was carried out by using the
NCSS 2007 statistical program (NCSS, East Kaysville, Utah, USA).
Error bars represent standard error of the mean (s.e.m.).
Results
TG2 expression in primary rat astrocytes
TG2 immunoreactivity is present in primary rat astrocyte in
vitro, but the intensity of the signal varied between cells (Fig. 1A).
Since we were interested in the role of TG2 in astrocytes under
inflammatory conditions, we studied the effect of various pro-
inflammatory cytokines on TG2 levels and activity. TG2 mRNA
levels were significantly increased after treatment with TNFa,
IL-1b and IFNc alone, while combinations of TNFa and IFNc,
or IFNc and IL-1b showed a synergistic increase in TG2 mRNA
transcript levels (Fig. 1B). TG2 protein levels could be visualised
on western blot (Fig. 1C) and showed a clear increase after
cytokine treatment, particularly after treatment with combina-
tions of cytokines. TG2 protein levels were quantified using a
specific TG2 ELISA. Like the mRNA levels, TG2 protein levels
in astrocytes were significantly elevated after all single cytokine
treatments (Fig. 1D). Moreover, all combined cytokine treat-
ments induced a synergistic increased level of TG2 protein
(Fig. 1D). Additionally, TG activity, present in cell lysates of
these astrocytes, is significantly increased after treatment with
TNFa and IL-1b alone, but not after treatment with IFNc.
However, the combined cytokine treatments all enhanced TG
activity with TNFa and IFNc giving a synergistic increase in
TG activity (Fig. 1E). As treatment with a combination of
cytokines resulted in the highest increase in TG2 expression and
activity, the combination of TNFa and IL-1b was used to
determine whether other TG family members are expressed by
astrocytes. Of all members studied, TG2 mRNA could be
detected under control conditions, which was enhanced after
cytokine treatment (Fig. 1F) as shown earlier (Fig. 1B).
Expression levels of TG1, TG3, TG6 and FXIIIa were
undetectable, even after treatment of the cells with the
combination of TNFa and IL-1b (Fig. 1F).
Figure 1. TG2 expression in primary rat astrocytes. A) TG2 is expressed in primary rat astrocytes as visualized by immunocytochemical analysis.
Scale bar: 50 mm. B) TG2 mRNA expression after treatment with various single cytokines or with cytokine combinations. C) TG2 protein expression
visualized by western-blot and D) measured with ELISA. E) TG2 activity levels measured with the TG Covtest TCMA. F) mRNA levels of
transglutaminase (TG) family members in primary rat astrocytes. Data are expressed as mean+s.e.m., n = 6 per condition (F: n = 3 per condition),
*P,0.05 compared to control, nd = not detectable.
doi:10.1371/journal.pone.0025037.g001
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Active TG2 on the surface of astrocytes
Using immunocytochemistry on non-fixed cells, we were able to
detect TG2 immunoreactivity located on or nearby the surface of
primary rat astrocytes (Fig. 2A). To measure semi-quantitative
changes in TG2 surface expression after treatment with cytokines,
cell surface biotinylation followed by TG2 immunoprecipitation
was performed. This resulted in a clear increase in the amount of
TG2 protein present on the surface of astrocytes, again most
dramatically when cells were treated with combinations of cytokines
(Fig. 2B). Treatment with single cytokines resulted in an increased
TG2 surface expression ranging from ,46 to ,96 the expression
in untreated (control) astrocytes whereas treatment with the various
combinations of cytokines resulted in a ,406 to ,766 elevated
expression compared to untreated (control) cells. A treatment of
single and combinations of IL-1b and TNFa were used for
subsequent experiments since this combination was equally effective
as the combination of TNFa and IFNc in enhancing total TG2
protein level and single treatments with TNFa and IL-1b showed
the highest increase in expression of surface TG2 which we
considered of importance for interaction with Fn.
To determine whether this surface associated TG2 is active, we
analyzed the incorporation of the competitive amine substrate
BAP onto the surface of astrocytes using FACS analysis (Fig. 2C–
G). Only cells negative for propidium iodide (PI) staining were
gated for analysis of fluorescent intensity (encircled cells in Fig. 2I).
The incorporation of BAP as measured by mean fluorescent
intensity is depicted in Fig. 2C. Astrocytes incubated in the
absence of BAP showed a background signal which is independent
from the cytokine treatment (Fig. 2C, dotted line in Fig. 2D–G).
BAP incorporation was already detectable in untreated (control)
astrocytes and clearly increased with 30% or 115% after treatment
with IL-1b or TNFa, respectively. Incubation of the astrocytes
with the combination of IL-1b and TNFa resulted in a two-fold
increase (200%) in mean fluorescent intensity (Fig. 2C, grey line in
Fig. 2D–G). The incorporation of BAP was significantly reduced
by 57% to 70% after treatment of the cells with the specific
irreversible TG2 inhibitor KCC009 compared to vehicle-treated
control or cytokine-treated astrocytes (Fig. 2C; black line in
Fig. 2D–G). Addition of the conjugate avidin-Alexa Fluor 488 only
to untreated astrocytes did not alter the fluorescent intensity of the
Figure 2. TG2 is expressed on the surface of rat astrocytes. A) Life non-permeabilized cells were immunofluorescently labeled to detect TG2
on the cell surface of rat astrocytes. Scale bar: 20 mm B) Cell surface-biotinylated proteins were immunoprecipitated, separated by SDS-PAGE, and
immunoblotted for TG2. Bands were semi-quantified and expressed as % compared to control. C) FACS analysis of BAP incorporation on the surface
of control rat astrocytes or astrocytes treated with IL-1b, TNFa or IL-1b+TNFa in the absence or presence of KCC009. Data represent mean fluorescent
intensity from 3 independent experiments. *P,0.05 versus vehicle-treated control cells, #P,0.05 versus vehicle-treated control or matched cytokine-
treated. D–G) FACS plots of BAP incorporation on the surface of rat astrocytes D) untreated or treated with E) IL-1b, F) TNFa or G) IL-1b+TNFa and
subsequent inhibition of TG2 activity. Dotted line: vehicle 2 BAP treated astrocytes; grey line: vehicle + BAP treated astrocytes; black line: KCC009 +
BAP treated astrocytes H) Effect of conjugate (avidin-Alexa Fluor-488). Grey line: untreated cells –BAP2avidine-Alexa Fluor, black line: untreated cells
–BAP+avidine-Alexa Fluor 488. I) Encircled astrocytes which were PI negative were gated for BAP.
doi:10.1371/journal.pone.0025037.g002
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cells compared to untreated cells incubated without avidin-Alexa
Fluor 488 (Fig. 2H).
Astrocyte-derived TG2 interacts with fibronectin
Since TG2 was present and active on the surface of astrocytes,
we questioned whether it plays a role in the interaction of the
astrocytes with Fn. Therefore, we studied the incorporation of the
competitive amine substrate BAP into Fn [28]. Astrocytes were
treated with cytokines for 48 hours and subsequently, cells were
plated onto Fn coated wells in serum free medium containing the
competitive amine substrate BAP. After incubation, cells were
extracted with deoxycholate containing buffer to eliminate the
astrocytes leaving the Fn coating intact. BAP covalently incorpo-
rated by astrocyte-derived TG2 into extracellular Fn was
quantified. Compared to vehicle-treated (control) cells, the amount
of BAP incorporated into Fn was significantly increased by 1.5 or 2
times after treatment with TNFa or IL-1b, respectively (Fig. 3).
The combination of these cytokines synergistically increased the
amount of incorporated BAP by approximately 17 times (Fig. 3).
To confirm that TG2 (partly) contributes to the BAP incorpora-
tion into Fn, rat astrocytes were co-incubated with the TG2
activity inhibitor KCC009. Incubation of cells with this inhibitor
resulted in significantly reduced incorporation of BAP into Fn
compared to matched vehicle-treated astrocytes (Fig. 3).
Inhibition of TG2 activity reduced astrocyte adhesion
onto fibronectin
To determine whether TG2 plays a role in adhesion of rat
astrocytes onto Fn, a quantitative adhesion assay was performed.
When astrocytes were cultured in the presence of IL-1b, TNFa or
the combination of these cytokines, astrocyte adhesion onto Fn
was increased by 110%, 56% or 64%, respectively compared to
vehicle-treated (control) cells (Fig. 4A). Treatment with the TG2
activity inhibitor KCC009 significantly reduced the amount of
adherent cells compared to vehicle-treated cells (Fig. 4A).
As a control, we checked whether KCC009 indeed reduced TG
activity in astrocytes. We already showed in Fig. 2C that KCC009
treatment reduced TG2 activity on the surface of astrocytes.
Indeed, co-incubation of the cytokines with KCC009 significantly
reduced TG activity in the astrocytes, although it did not return to
control levels (Fig. 4B). Of importance was that cytokine and/or
KCC009 treatment did not affect astrocyte viability as measured
with a propidium iodide assay (Fig. 4C).
Inhibition of TG2 activity reduced migration of astrocytes
across fibronectin
To analyze the involvement of TG2 in migration of cytokine-
stimulated astrocytes, a quantitative migration assay was per-
formed. Astrocytes were plated onto Fn coated wells and, after
adherence, a scratch wound was induced to stimulate astrocyte
migration in a monolayer. At first the migration of vehicle-treated
control astrocytes was compared to vehicle-treated, cytokine-
treated cells (Fig. 5A).
The initial wound diameter was similar for all conditions tested
at t = 0 (,400 mm). At 16 h after wounding, the diameter reduced
to approximately 70 mm in vehicle-treated control astrocytes
(Fig. 5B). Treatment with IL-1b, TNFa or the combination of IL-
1b and TNFa resulted in an altered migration capacity of
astrocytes (Fig. 5B). Cells cultured in the presence of TNFa
showed an increased migration and reduced the gap to
approximately 30 mm, whereas treatment with IL-1b or the
combination of TNFa and IL-1b reduced astrocyte migration
leaving a wound diameter of 180 mm and 260 mm respectively
(Fig. 5B) Secondly, the migration of KCC009-treated astrocytes
was compared to that of vehicle-treated cells. At 16 h after
wounding, inhibition of TG2 activity with KCC009 in both
control and cytokine-treated astrocytes significantly reduced
migration compared to vehicle-treated control and matched
cytokine-treated cells (Fig. 5A,B). Upon inducing the scratch, the
Fn coating in the wells are damaged (Fig. S1). However, both the
vehicle and KCC009-treated astrocytes are able to produce Fn
and recover the damaged Fn layer (Fig. S1).
To determine whether altered migration was due to effects on
cell proliferation, the nuclear uptake of BrdU was measured.
Culturing the cells in the presence of IL-1b, TNFa or the
combination of IL-1b and TNFa significantly increased the
nuclear uptake of BrdU by 50%, 140% and 207%, respectively
compared to vehicle-treated control astrocytes (Fig. 5C). More-
over, inhibition of TG2 activity by KCC009 significantly
decreased BrdU uptake compared to vehicle-treated control and
matched cytokine-treated cells (Fig. 5C). It is of interest to note
that a similar reduced level of astrocyte proliferation was found
independent of cytokine treatment.
Cytokine induced TG2 activity is involved in focal
adhesion formation
Cellular adhesion and migration is partly mediated by an
intracellular focal adhesion complex that links cell surface integrins
to the actin cytoskeleton via integrin receptors and adaptor
proteins such as vinculin [31]. F-actin was visualized using
rhodamine-phalloidin and was organized in fine bundles that
were orientated along the cellular axis. Vehicle-treated control
astrocytes exhibit vinculin positive focal adhesions at the tip of F-
actin stress fibers (Fig. 6A, arrows). When cells were cultured in the
presence of IL-1b, TNFa or the combination of both cytokines,
vinculin positive focal adhesions were still present, but less
prominent, particularly after TNFa treatment (Fig. 6A). Com-
pared to vehicle-treated cells, inhibition of TG2 activity with
KCC009 induced a dramatic redistribution of immunoreactive
vinculin, from a focal to a diffuse pattern (Fig. 6A) in both vehicle-
treated and cytokine-treated astrocytes. Western blot analysis was
performed to study the relative protein levels of vinculin. Bands
were semi-quantified and corrected for b-actin expression levels.
Treatment with IL-1b did not alter the level of vinculin protein. In
contrast, vinculin protein levels were reduced after treatment with
TNFa or the combination of IL-1b and TNFa (Fig. 6A,B).
Treatment with KCC009 did neither affect vinculin levels in
Figure 3. Incorporation of BAP into Fn by rat astrocyte-derived
TG2. Data represent mean values 6 s.e.m. from a representative
experiment, n = 5 for each data point. *P,0.05 versus vehicle-treated
control cells, #P,0.05 versus vehicle-treated control or matched
cytokine-treated cells.
doi:10.1371/journal.pone.0025037.g003
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Figure 4. The effect of cytokine treatment and inhibition of TG2 activity on the adhesion capacity of astrocytes onto Fn. A) Adhesion
of rat astrocytes onto Fn coated wells after treatment with cytokines and subsequent inhibition of TG2 activity. B) TG activity after treatment with
cytokines and subsequent inhibition of TG2 activity. C) Cell viability measured using the propidium iodide assay. Data are expressed as mean+s.e.m.,
n = 15 (A) or n = 5 per condition (B,C), #P,0.001 versus vehicle-treated control cells and *P,0.05, **P,0.01, ***P,0.001 versus vehicle-treated
control or matched cytokine-treated cells.
doi:10.1371/journal.pone.0025037.g004
Figure 5. The effect of cytokine treatment and inhibition of TG2 activity on the migration capacity of astrocytes. A) A scratch wound
was made in an astrocyte confluent cell layer plated onto Fn and astrocytes were allowed to migrate in the presence of vehicle or 0.5 mM KCC009.
Cells were fixed after 0 and 16 h and stained with rhodamine-phalloidin to visualize the cells and wound diameter. Scale bar: 200 mm. B)
Quantification of wound diameter after migration of rat astrocytes. Astrocytes were allowed to migrate for 16 h and the surface of the wound was
quantified using phase-contrast microscopy after 0 and 16 h. C) BrdU incorporation after cytokine treatment and subsequent TG2 inhibition. Data
represent mean+s.e.m. from a single experiment using 5 measurements per condition/time point and is representative out of 3 separate experiments.
*P,0.05 versus vehicle-treated control cells, **P,0.01 versus vehicle-treated control cells, #P,0.01 versus vehicle-treated control or matched
cytokine-treated cells.
doi:10.1371/journal.pone.0025037.g005
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vehicle-treated nor in TNFa-treated astrocytes. KCC009 treat-
ment only slightly reduced levels of vinculin protein in IL-1b and
the combination of IL-1b and TNFa treated cells (Fig. 6B).
Discussion
In the present study, we demonstrate that TG2 expression and
activity is present in primary rat astrocytes and is increased after
treatment with pro-inflammatory cytokines. Moreover, active
TG2 is present on the surface of astrocytes, enhanced by cytokine
exposure, and interacts with Fn to contribute to astrocyte adhesion
and migration.
Our study provides evidence that pro-inflammatory cytokines, in
particular TNFa, IL-1b and IFNc or combinations of these cytokines
enhance intracellular and cell-surface expression of TG2, even after
two days of cytokine treatment. A relatively long-term expression of
TG2 in these cells is of interest as under chronic neuropathological
conditions TG2 appeared in astrocytes localized within and at the
border of active MS lesions [29] and TG2 has been found in
astrocytes surrounding lesions in experimental NeuroAIDS [32]. In
active MS lesions, particularly leukocytes and lymphocytes produce
inflammatory mediators, including IL-1b, TNFa and IFNc. We
therefore studied the effect of these cytokines on the expression and
activity level of astrocytic TG2. As shown, these cytokines
individually, and particularly combinations of them, enhance TG2
mRNA and protein levels as well as activity. So far, it has been
reported that TNFa and particularly IL-1b elevate TG2 mRNA and
protein levels in astrocytes [33]. The synergistically elevated levels of
TG2 induced by treatment with combinations of cytokines are in
concordance with observations on synergistic effects such as
activation of the MAPK pathway and regulation of matrix
metalloproteases and chemokines in various other cell types [34–
36]. The molecular mechanisms underlying this synergistic effect of
cytokines involve cooperative activation of transcription factors [37].
As we hypothesized that astrocyte-derived TG2 is involved in
the interaction with the extracellular matrix, it is of importance to
know whether TG2 is present on the cell surface. Indeed, TG2
protein is present on the astrocyte surface, and these TG2 surface
levels are enhanced after exposure to the inflammatory cytokines.
Previously, surface TG2 on epithelial cells was found to be
increased by the cytokine TGFb [38]. In addition, TG2 localized
on the astrocyte surface is enzymatically active as determined by
incorporation of BAP, an amine substrate for transglutaminases,
using FACS analysis. TG activity on the astrocyte surface is also
enhanced by treatment of the cells with inflammatory cytokines.
To our knowledge, this is the first observation of TG activity on
the astrocyte surface to be regulated by inflammatory cytokines.
The fact that the observed mean fluorescence intensity could be
greatly reduced by the TG2 specific inhibitor KCC009, indicates
that TG activity on the surface of astrocytes is largely due to TG2.
The observation that the fluorescence intensity of astrocytes
incubated with the streptavidin-Alexa Fluor-488 conjugate is
similar to that of completely untreated astrocytes indicates that
with flow cytometry we solely detect BAP incorporation on the cell
surface and not BAP incorporation inside the cell. This assay has
also been used to study the cell surface levels of TG2 on the surface
of other cells such as osteoblasts [39]. To determine whether this
astrocyte-derived TG2 could play a role in ECM rearrangement,
we studied the interaction between rat astrocytes and Fn, an
important ECM protein in MS lesions [40–42]. We observed that
the enhanced TG2 activity in and on the cell surface upon
cytokine treatment was accompanied by an increased astrocyte
adhesion onto Fn and that inhibition of TG2 activity, at least
partly, reduced astrocyte adhesion. How astrocyte-derived TG2
contributes to the adhesion between astrocytes and Fn is
uncertain. It could be due to high-affinity binding of surface
TG2 to Fn [43] via interaction with its gelatin-binding domain
[44,45]. The interaction between astrocytes and Fn might also be
Figure 6. The effect of cytokine treatment and inhibition of TG2 activity on cytoskeletal rearrangements and RhoA activity. A)
Confocal images of cells stained with rhodamin phalloidin (red) and an antibody against vinculin (green). Scale bar: 10 mm. B) Representative western
blot of vinculin and b-Actin (n = 3). Semi-quantitative analysis of vinculin levels were corrected for b-Actin and the untreated control was set at 100%.
The corrected levels are shown under the vinculin-blot. Cells were cultured in medium alone or medium containing IL-1b, TNFa or the combination
for 48 h. Subsequently, cells were treated as follows: 1 = untreated, 2 = vehicle-treated, 3 = KCC009-treated.
doi:10.1371/journal.pone.0025037.g006
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attributed to cell surface TG2 complexed with b-integrins to
enhance the affinity for binding to Fn as it has been shown for
monocytes [44] and breast cancer cells [46]. Recently, it has been
shown that the interaction of TG2 and Fn on the surface of
osteoblasts was mediated via other surface receptors such as cell
surface heparan sulphate proteoglycans including syndecan-2 and
syndecan-4 [47]. Alternatively, TG2 present on the surface of
endothelial cells has been demonstrated to contribute, via its cross-
linking activity, to the interaction with Fn [28]. The observation
that astrocyte-derived TG2 is able to incorporate BAP into Fn
suggests that the active site of TG2, known to be involved in cross-
linking activity, is of importance in the interaction between rat
astrocytes and Fn. Still, we cannot exclude a contribution of direct
binding between TG2 and Fn to play a role in the interaction
between astrocytes and Fn.
As it is known that TG2 catalysed protein cross-links are stable to
proteolytic and mechanical damage [21], TG2 activity on the
surface of astrocytes might facilitate increased stability and
resistance to degradation of modified ECM proteins such as Fn.
Rat astrocytes treated with IL-1b or the combination of IL-1b and
TNFa displayed reduced migration across Fn which is in line with
previous observations showing that treatment of human astrocytes
with IL-1b attenuated migration across Fn [9]. In contrast, treatment
with TNFa only resulted in an increased migration capacity of rat
astrocytes as observed in other cell types, including cancer cells and
mesenchymal stem cells [48,49]. Taken together, our data suggest
cytokine-specific regulation of astrocyte migration. This is confirmed
by observations in neural precursor cells showing that IL-1b, but not
TNFa, reduce migration of these cells [50].
The role of TG2 in astrocyte migration was determined by
inhibiting its activity using KCC009. Reduction of TG2 activity in
cytokine-treated rat astrocytes further decreased astrocyte migration
capacity compared to matched vehicle-treated cells, suggesting that
TG2 activity plays a role cell migration. It is good to note that if TG2
activity is indeed of importance in cell migration, then the observation
that astrocytes treated either with IL-1b only or the combination of
IL-1b and TNFa showed reduced migration is counterintuitive,
because under these conditions TG2 activity is increased in and on
the cells. Thus, our data indicate that TG2 is of importance in TNFa-
induced migration of astrocytes, whereas its role in IL-1b-mediated
effects on migration is probably less prominent.
The effect of cytokines on astrocyte migration is unlikely to be
attributed to altered proliferation, because the combination of IL-
1b and TNFb showed the least migration, but most proliferation
of astrocytes. Moreover, inhibition of TG2 activity by KCC009
similarly attenuated astrocyte proliferation independent of cyto-
kine treatment, which is thus not responsible for the cytokine-
specific effects on migration observed. Of importance to note is
that upon a scratch wound is made, the Fn matrix is damaged (Fig.
S1, vehicle t = 0 h). Upon longer incubation, the primary rat
astrocytes were able to produce and deposit Fn to a similar extent
after treatment with vehicle or KCC009 (Fig. S1, vehicle or
KCC009 t = 24 h, left side of dotted lines). However, KCC009-
treated astrocytes migrate less, and thus deposit less Fn (Fig. S1,
vehicle or KCC009 t = 24 h, right side of dotted lines, arrows). We
thus consider that KCC009 does not clearly affect the assembly of
Fn, but rather affects TG2 activity in and on the astrocytes which
is of importance for cell migration.
Astrocyte adhesion and migration are multistep processes
involving formation and stabilisation of focal adhesions which
are necessary for cell adhesion, and dissolution of focal adhesions
to mediate cell migration. These focal adhesions link the
extracellular matrix to the cytoskeleton via integrin receptors
and adapter proteins such as vinculin [31]. Treatment with TNFa
or the combination of IL-1b and TNFa reduced vinculin protein
levels, whereas treatment with IL-1b had no effect. This may
explain our observation that IL-1b-treated astrocytes show little
migration, whereas loss of vinculin, indicative for dissolution of
focal adhesions is observed in TNFa-treated astrocytes that do
migrate. Immunocytochemically, vinculin immunoreactivity
seemed, although not quantified, less prominent at the tip of F-
actin fibers of TNFa-treated astrocytes, particularly. This again
supports the positive effect of TNFa on astrocyte migration. Our
data are in agreement with the observation that TNFa regulates
cytoskeletal organization and dispersion of vinculin from focal
adhesion sites, resulting in increased migration of smooth muscle
cells [51].
After inhibition of TG2 activity by KCC009 treatment, vinculin
protein levels were hardly affected, suggesting that cytokine-
enhanced TG2 does not clearly contribute to the reduction in
vinculin protein levels. However, inhibition of TG2 activity by
KCC009 does result in a dramatic intracellular redistribution of
vinculin as observed immunocytochemically, from a focal to a
diffuse cytoplasmic localization pattern. Now under all conditions,
the localization of vinculin at the tip of F-actin fibers has
disappeared. Unexpectedly, migration of astrocytes is not
enhanced under these conditions. The reduced TG2 activity
resulting in the intracellular redistribution of vinculin may now
have affected the focal adhesions in such a way that migration is
impaired. Thus, TG2 is an important factor in necessary for
interaction of astrocytes with the ECM, i.e. Fn.
All together, our data support a role for TG2 in astrocyte
adhesion and migration, but we cannot conclude whether surface-
associated TG2 or intracellular TG2 plays a more prominent role in
these processes. It has been shown that intracellular TG2 can
induce activation of NFkB, an inflammatory transcription factor,
which in turn can regulate downstream processes such as cell
survival and spreading [52,53]. Moreover, enhanced nitric oxide
levels in fibroblasts reduced intracellular and extracellular TG2
activity and subsequent activation of TGFb in an NFkB dependent
manner, ultimately resulting in reduced ECM remodelling [19].
Furthermore, activation of focal adhesion kinase (FAK) has been
linked to TG2 expression that results in increased motility,
independent of surface expression of TG2 in tumor cells [54].
However, in osteoblasts and mesenchymal stem cells it was shown
that FAK activation and subsequent effects on adhesion and
migration is dependent on cell surface TG2 activity levels [47,55].
In summary, we have shown that TG2 expression and activity
present in and on the surface of rat astrocytes is enhanced upon
cytokine treatment. This coincides with an increased adhesion to
and interaction of the astrocytes with the ECM protein Fn.
Inhibition of TG2 activity reduced the adhesion of astrocytes onto
Fn. Interestingly, cytokine-specific effects on cell migration were
observed, but inhibition of TG2 activity reduced astrocyte
migration independent of cytokine treatment. Furthermore,
inhibition of TG2 activity resulted in altered focal adhesion
formation which is necessary for astrocyte-ECM interaction. All
together, we put forward that under chronic neuroinflammatory
conditions, e.g. MS, TG2 activity in and on the surface of
astrocytes is involved in remodeling of the ECM, in particular by
interacting with Fn and possibly other ECM proteins. Concomit-
tant effects on astrocyte adhesion and migration may ultimately
facilitate glial scar formation.
Supporting Information
Figure S1 Presence of fibronectin besides and in the
scratched wound before and after migration of primary
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rat astrocytes. Primary rat astrocytes were plated onto
fibronectin coated wells and treated with cytokines (IL-1b+TNFa,
50 ng/ml each) for 48 hours. Then, a scratch wound was made
and cells were allowed to migrate in the presence of vehicle or
0.5 mM KCC009. At 0 and 24 h after wound induction, the
astrocytes were eliminated using 0.1% sodium-deoxycholate
(Sigma) for 20 min. The ‘‘empty’’ wells were subsequently fixed
with 4% paraformaldehyde, and stained for fibronectin (rabbit
anti-human fibronectin, 1:1,000; Sigma-Aldrich). The presence of
fibronectin besides (at the left side of the dotted line) and in the
wound (at the right side of the dotted line) was visualized.
Fibronectin was reduced at the site of the wound after inducing a
scratch wound (t = 0) but produced and deposited again by vehicle
and KCC009 treated astrocytes (t = 24 h, vehicle and KCC009,
left from dotted line). However, the KCC009-treated astrocytes
migrated to a lesser extent than vehicle-treated astrocytes, and thus
less Fn is present (t = 24 h, vehicle and KCC009, right from dotted
line). Scale bar: 200 mm.
(TIF)
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